
1. Sci Rep. 2021 Oct 26;11(1):21126. doi: 10.1038/s41598-021-00560-8.

Evaluation of a saliva molecular point of care for the detection of SARS-CoV-2 in
ambulatory care.

LeGoff J(1)(2), Kernéis S(#)(3)(4)(5), Elie C(#)(6)(7), Mercier-Delarue S(8),
Gastli N(9), Choupeaux L(6), Fourgeaud J(10), Alby ML(11), Quentin P(11), Pavie
J(12)(13), Brazille P(12)(13), Néré ML(8), Minier M(8), Gabassi A(8), Leroy
C(9)(14), Parfait B(15), Tréluyer JM(#)(6)(7), Delaugerre C(#)(8)(16).

Author information: 
(1)Virologie, AP-HP, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010,
Paris, France. jerome.le-goff@aphp.fr.
(2)INSERM, Equipe INSIGHT, U976, 75010, Université de Paris, Paris, France.
jerome.le-goff@aphp.fr.
(3)INSERM, IAME, Université de Paris, 75018, Paris, France.
(4)Equipe de Prévention du Risque Infectieux, AP-HP, Hôpital Bichat, 75018,
Paris, France.
(5)Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion, 75015,
Paris, France.
(6)Clinical Research Unit / Clinical Investigation Center, APHP, Necker-Enfants
Malades Hospital, 75015, Paris, France.
(7)EA 7323 Pharmacologie et Thérapeutique de l'enfant et de la Femme Enceinte,
Université de Paris, 75015, Paris, France.
(8)Virologie, AP-HP, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010,
Paris, France.
(9)Plateforme Covid IDF, AP-HP Centre, 75014, Paris, France.
(10)Virologie, AP-HP, Hôpital Necker-Enfants Malades, 75015, Paris, France.
(11)Centre de Dépistage COVISAN 13 14 15, Communauté Professionnelle de
Territoire de Santé, 75014, Paris, France.
(12)Immuno-Infectiologie, AP-HP, Hôtel Dieu, 75004, Paris, France.
(13)Centre de Dépistage COVISAN, AP-HP, Hôtel-Dieu, 75004, Paris, France.
(14)Plateforme SeqOIA, AP-HP, 75014, Paris, France.
(15)Centre de Ressources Biologiques, Hôpital Cochin, 75014, Paris, France.
(16)INSERM, U944, 75010, Université de Paris, Paris, France.
(#)Contributed equally

Rapid identification of SARS-CoV-2-infected individuals is a cornerstone for the 
control of virus spread. The sensitivity of SARS-CoV-2 RNA detection by RT-PCR is
similar in saliva and nasopharyngeal swabs. Rapid molecular point-of-care tests
in saliva could facilitate, broaden and speed up the diagnosis. We conducted a
prospective study in two community COVID-19 screening centers to evaluate the
performances of a CE-marked RT-LAMP assay (EasyCoV) designed for the detection of
SARS-CoV2 RNA from fresh saliva samples, compared to nasopharyngeal RT-PCR, to
saliva RT-PCR and to nasopharyngeal antigen testing. Overall, 117 of the 1718
participants (7%) tested positive with nasopharyngeal RT-PCR. Compared to
nasopharyngeal RT-PCR, the sensitivity and specificity of the RT-LAMP assay in
saliva were 34% and 97%, respectively. The Ct values of nasopharyngeal RT-PCR
were significantly lower in the 40 true positive subjects with saliva RT-LAMP (Ct
25.9) than in the 48 false negative subjects with saliva RT-LAMP (Ct 28.4)
(p = 0.028). Considering six alternate criteria for reference tests, including
saliva RT-PCR and nasopharyngeal antigen, the sensitivity of saliva RT-LAMP
ranged between 27 and 44%. The detection of SARS-CoV-2 in crude saliva samples
with an RT-LAMP assay had a lower sensitivity than nasopharyngeal RT-PCR, saliva 
RT-PCR and nasopharyngeal antigen testing.Registration number: NCT04578509.

© 2021. The Author(s).

DOI: 10.1038/s41598-021-00560-8 
PMCID: PMC8548486
PMID: 34702867  [Indexed for MEDLINE]

